Oral fluoropyrimidines in colorectal cancer

Seminars in Oncology

Volumn 27, Issue 5 SUPPL. 10, 2000, Pages 91-95

  Van Cutsem, E ^a   Peeters, M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; ALPHA INTERFERON; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; METHOTREXATE; OXONIC ACID; SPARFOSIC ACID; TEGAFUR; TRIMETREXATE; URACIL;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG ABSORPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VASCULAR ACCESS;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG COMBINATIONS; FLUOROURACIL; HUMAN; LEUCOVORIN; OXONIC ACID; PYRIDINES; TEGAFUR; URACIL;

EID: 0033790705     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Fluorinated pyrimidine. A new class of tumor inhibitory compounds
2. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study
3. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
4. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule
5. Developments in fluoropyrimidine therapy for gastrointestinal cancer
6. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
7. Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer
8. Fluoropyrimidines: A critical evaluation
9. Patient preferences for oral versus intravenous palliative chemotherapy
10. Experience with UFT in Japan
11. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
12. Oral fluoropyrimidines in the treatment of colorectal cancer
13. Uracil-ftorafur: An oral fluoropyrimidine active in colorectal cancer
14. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer
15. Randomized comparative study of ORZEL (oral uracil/tegafur) (UFT) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic cancer
16. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer
17. Phase II trial of uracil/ftorafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study
18. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
19. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
20. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
21. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer. Results of a randomized phase II study
22. A phase III trial (S014796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
23. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
24. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil
25. 5-Ethynyluracil (776C85): Modulation of 5-FU efficacy and therapeutic index in rats bearing advanced colorectal carcinoma
26. A phase II trial of a seven day regimen of oral 778C85 plus a five day regimen of oral 5-fluorouracil (5-FU) in untreated patients with metastatic colorectal cancer: A North Central Treatment Group Study
27. A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer
28. Development of a novel form of oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
29. 1 (1 M tegafur 0.4 M gimestat 1 M otostatpotassium) in advanced gastric cancer patients